Pertussis and the acellular vaccines
DOI:
https://doi.org/10.33321/cdi.1996.20.24Abstract
Morbidity and mortality from pertussis continue to be a problem worldwide, both because the organism is difficult to eradicate and because there is non-compliance with vaccination, often owing to concerns about side effects of the whole-cell vaccine. The new acellular vaccines have fewer side effects and appear to be efficacious, although costly. Some have been approved in other countries for use in infants and children, but none is yet available in Australia. Once they are introduced, careful surveillance will be needed to monitor any epidemiological changes.
Downloads
References
Hansman DJ. Whooping cough: diagnosis, prevalence and prevention [editorial]. Med J Aust 1987; 146:511-513.
Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ 1988; 296:612-614.
Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA 1995; 273:1044-1046.
Grob PR, Crowder MJ, Robbins JF. Effect of vaccination on severity and dissemination of whooping cough. BMJ 1981; 282:1925-1928.
Granström G, Sterner G, Nord CE, Granström M. Use of erythromycin to prevent pertussis in newborns of mothers with pertussis. J Infect Dis 1987; 155:1210-1214.
De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 1995; 14:969-975.
Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870-874.
Fine PEM. Herd immunity: history, theory, practise. Epidemiol Rev 1993; 15:265-302.
Syedabubakar SN, Matthews RC, Preston NW, et al. Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK. Epidemiol Infect 1995; 115:101-113.
Communicable Diseases Surveillance. Comm Dis Intell 1995; 19:545. 1996; 20:21.
Centre for Disease Control. Pertussis – United States, January 1992-June 1995. MMWR Morb Mort Wkly Rep 1995; 44:525-9.
Christie CDC, Marx ML, Marchant CD, Reising SF. The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med 1994; 331:16-21.
Preston NW, Carter EJ. Serotype specificity of vaccine-induced immunity to pertussis. Comm Dis Rep 1992; 2:R155-R156.
Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Comm Dis Rep 1992; 2:R152-R154.
Gapes M. Pertussis in Sydney 1971-1993. Paper presented at the Australian Society of Microbiology, Annual Scientific Meeting Sydney. May 1984.
Harris G, Nolan T, Hartman L. Clinical signs associated with Triple Antigen (DTP) vaccination in infants. J Paediatr Child Health 1995; 31:228-232.
Feery BJ, Finger WK, Kortus Z, Jones GA. The incidence and type of reactions to plain and adsorbed DTP vaccines. Aust Paediatr J 1985; 21:91-95.
World Health Organization. WHO Expert Committee on Biological Standardization; Thirtieth Report. Technical Report Series No. 638:61- 65. Geneva:WHO, 1979.
Preston NW, Matthews RC. Transmission of pertussis: do adults have an important role? Lancet 1996; 347:129-130.
Wirsing von König CH, Postels-Multani S, Block HL, Schmitt HJ. Transmission of pertussis: do adults have an important role? Lancet 1996; 347:129-130.
Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987; 9:866-883.
Preston NW. Pertussis today. In: Wardlaw AC, Parton R, editors. Pathogenesis and immunity in pertussis. Chichester: John Wiley, 1988.
Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med 1995; 333:1045-1050.
Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protecting efficacy and adverse events. Lancet 1988; 1:955-960.
Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-348.
Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-355.
Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96 (suppl); 548-557.
Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96 (suppl): 557-566.
Poland GA. Acellular pertussis vaccines: new vaccines for an old disease [editorial]. Lancet 1996; 347:209-210.
Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334:391-392.
Schmitt HJ, Wirsing von K‘nig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275:37-41.
Gale JL, Thapa PB, Wassilak SGF, et al. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine: a population-based case-control study. JAMA 1994; 271:37-41.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
